Max Star

Max Star, on behalf of Rajan Sharma, asked about the expected progression of R&D costs in 2025 and the design of the lung cancer trial regarding response rate assessment. He also questioned the decline in mRNA integrity shown in the LNP stability data.

Answer

CFO Axel-Sven Malkomes noted that while R&D spending will support pipeline advancement, the company remains focused on cost efficiencies. CSO Myriam Mendila confirmed the lung cancer trial will measure for tumor shrinkage and other efficacy endpoints after adding the vaccine to patients stable on pembrolizumab. She clarified that the mRNA integrity shown in the stability data after 12 months at room temperature remains within regulatory specifications.

Asked about the outlook for R&D costs in 2025, the clinical trial design for measuring response in the lung cancer trial, and the mRNA stability data presented.

Answer

R&D costs will be focused on the core pipeline while the company continues to seek cost efficiencies. In the lung cancer trial, patients stable on pembrolizumab will receive the vaccine, and efficacy will be measured by tumor response, progression-free survival, and other endpoints. The observed decline in mRNA integrity at room temperature after one year is still within regulatory specifications and considered encouraging.